ES2132068T3 - Factor inhibidor de la sintesis de la citoquina y metodos para usarlo. - Google Patents

Factor inhibidor de la sintesis de la citoquina y metodos para usarlo.

Info

Publication number
ES2132068T3
ES2132068T3 ES90911213T ES90911213T ES2132068T3 ES 2132068 T3 ES2132068 T3 ES 2132068T3 ES 90911213 T ES90911213 T ES 90911213T ES 90911213 T ES90911213 T ES 90911213T ES 2132068 T3 ES2132068 T3 ES 2132068T3
Authority
ES
Spain
Prior art keywords
methods
cytokine synthesis
synthesis inhibitor
cytokine
inhibitor factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911213T
Other languages
English (en)
Inventor
Timothy R Wedgewood Cr Mosmann
Kevin W Moore
Martha W Bond
Paulo J M Vieira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2132068T3 publication Critical patent/ES2132068T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PREVEN PROTEINAS Y GENES DE MAMIFEROS, CONCEBIDOS COMO FACTORES INHIBIDORES DE CITOKINA (CSIFS), QUE SON CAPACES DE INHIBIR LA SINTESIS DE LAS CITOKINAS ASOCIADAS CON RESPUESTAS DE TIPO HIPERSENSITIVO RETARDADAS Y QUE JUNTO CON SUS ANTAGONISTAS SON UTILES EN EL TRATAMIENTO DE LAS ENFERMEDADES ASOCIADAS CON DESEQUILIBRIOS DE CITOKINA, COMO SON LA LEISMANIASIS Y OTRAS INFECCIONES PARASITARIAS, Y CIERTOS DESORDENES INMUNOLOGICOS QUE INCLUYEN MHC ASOCIADOS CON ENFERMEDADES AUTOINMUNES CAUSADAS POR EL EXCESO DE PRODUCCION DE INTERFERON
ES90911213T 1989-06-28 1990-06-28 Factor inhibidor de la sintesis de la citoquina y metodos para usarlo. Expired - Lifetime ES2132068T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
ES2132068T3 true ES2132068T3 (es) 1999-08-16

Family

ID=27005854

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911213T Expired - Lifetime ES2132068T3 (es) 1989-06-28 1990-06-28 Factor inhibidor de la sintesis de la citoquina y metodos para usarlo.

Country Status (22)

Country Link
EP (2) EP0567450B1 (es)
JP (1) JP2813063B2 (es)
KR (1) KR0183035B1 (es)
CN (3) CN1051393A (es)
AT (1) ATE180833T1 (es)
AU (1) AU635058B2 (es)
CA (1) CA2062763C (es)
CS (1) CS414591A3 (es)
DE (1) DE69033143T2 (es)
DK (1) DK0567450T3 (es)
ES (1) ES2132068T3 (es)
FI (1) FI107926B (es)
GR (1) GR3030404T3 (es)
HK (3) HK1008834A1 (es)
HU (1) HU216310B (es)
IL (1) IL94878A (es)
NO (1) NO301718B1 (es)
NZ (1) NZ234291A (es)
PT (1) PT94514B (es)
SG (1) SG52282A1 (es)
TW (1) TW218383B (es)
WO (1) WO1991000349A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
ATE116550T1 (de) * 1991-01-16 1995-01-15 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE69203443T2 (de) * 1991-01-16 1995-12-07 Schering Corp Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
HU224437B1 (hu) * 1991-08-06 2005-09-28 Schering Corp. Eljárás interleukin-10 analógokat vagy antagonistákat tartalmazó endotoxin- vagy szuperantigén-indukált toxicitás kezelésére szolgáló gyógyszerkészítmények előállítására
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
JP3494647B2 (ja) * 1992-08-20 2004-02-09 シェリング・コーポレーション Ｉｌ−４および／またはｉｌ−１０ならびにそれらに対する抗体の新規な用途
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
CA2144648A1 (en) * 1992-09-18 1994-03-31 Mario Clerici Restoration of immunocompetency to t helper cells in hiv infected patients
CA2145863A1 (en) * 1992-10-01 1994-04-28 Martha W. Bond Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
CA2155109A1 (en) * 1993-02-01 1994-08-18 Daniel Abramowicz Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
SK150596A3 (en) * 1993-07-26 1997-04-09 Schering Corp Agonists and antagonists of human interleukin-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
BR9508243A (pt) * 1994-07-05 1997-10-21 Steeno Res Group As Imunomoduladores
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN101307106B (zh) * 1995-12-13 2013-06-12 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
CN1216470A (zh) * 1996-04-17 1999-05-12 帕特里克·T·普伦德加斯特 脱氢表雄酮组合治疗方法
WO1998009644A2 (en) * 1996-09-06 1998-03-12 Schering Corporation Method for lowering cholesterol levels
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
BR0109705A (pt) 2000-03-31 2005-01-11 Idec Pharma Corp Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
WO2011159881A2 (en) 2010-06-16 2011-12-22 Allergan, Inc. Il-10 and methods of treating ocular and other diseases
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3600414A1 (en) 2017-03-30 2020-02-05 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
PT96231B (pt) * 1989-12-20 1998-09-30 Schering Corp Metodo para a producao de proteinas bcrf1 uteis com inibidores do interferao gama e metodo para a sua utilizacao

Also Published As

Publication number Publication date
EP0567450A1 (en) 1993-11-03
JPH04502560A (ja) 1992-05-14
ATE180833T1 (de) 1999-06-15
NO915115D0 (no) 1991-12-27
IL94878A (en) 2003-01-12
SG52282A1 (en) 1998-09-28
HK1040531B (zh) 2008-01-11
PT94514B (pt) 1998-02-27
NO301718B1 (no) 1997-12-01
DK0567450T3 (da) 1999-12-13
FI916126A0 (fi) 1991-12-27
DE69033143T2 (de) 1999-10-21
HUT61048A (en) 1992-11-30
CN1317569A (zh) 2001-10-17
KR920701437A (ko) 1992-08-11
FI107926B (fi) 2001-10-31
HU216310B (hu) 1999-06-28
HU906705D0 (en) 1992-03-30
JP2813063B2 (ja) 1998-10-22
DE69033143D1 (de) 1999-07-08
EP0405980A1 (en) 1991-01-02
CN1318589C (zh) 2007-05-30
GR3030404T3 (en) 1999-09-30
NZ234291A (en) 1992-11-25
CN1051393A (zh) 1991-05-15
IL94878A0 (en) 1991-04-15
TW218383B (es) 1994-01-01
AU635058B2 (en) 1993-03-11
PT94514A (pt) 1991-04-18
HK1008834A1 (en) 1999-05-21
CA2062763A1 (en) 1990-12-29
CA2062763C (en) 2010-01-05
NO915115L (no) 1992-02-26
AU6077090A (en) 1991-01-17
HK1040493A1 (en) 2002-06-14
HK1040531A1 (en) 2002-06-14
CN1198642C (zh) 2005-04-27
EP0567450B1 (en) 1999-06-02
CN1317343A (zh) 2001-10-17
KR0183035B1 (ko) 1999-04-01
HK1040493B (zh) 2005-12-16
WO1991000349A1 (en) 1991-01-10
CS414591A3 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
ES2132068T3 (es) Factor inhibidor de la sintesis de la citoquina y metodos para usarlo.
ES2156852T3 (es) Citoquina mamifera, il-11.
IT8621411A0 (it) Padiglione smontabile particolarmente per il ricovero temporaneo di persone.
ES2113980T3 (es) Ligandos solubles para cd40.
FI935585A (fi) Pyrrolopyrimidiinit
DK0604418T3 (da) Isolerede viralproteincytokinantagonister
AR013441A1 (es) Un compuesto de imidazoquinoxalina, metodo para el tratamiento de un padecimiento o desorden asociado con la proteina tirosinaquinasa, lascomposiciones farmaceuticas que las contienen y metodos para preparar dichos compuestos y sus intermediarios
IT8721005A0 (it) Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale.
IT1206730B (it) Amidi ed esteri di diidropiridinildicarbossilato farmaceuticamente utili.
IT8947803A0 (it) Procedimento per la produzione di semilavorati di cuoio
PT91750A (pt) Processo para a preparacao de factor de crescimento de celulas t auxiliares
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
ATE111357T1 (de) Synergetische immunostimulierende zusammensetzung und ihre verwendung.
DK0723552T3 (da) Oligopeptider afledt af fragmenter af C-reaktivt protein
IT8721560A0 (it) Procedimento per la purificazione di interferone.
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi
IT8021790A0 (it) Metodo per il frazionamento controllato di proteine.
ES2062317T3 (es) Procedimiento e intermedios para la preparacion de 3s-amino-2r-hidroxi-alcanoatos de isopropilo.
IT8945801A0 (it) Procedimento per la fabbricazione di pannelli sagomati per mobili
BR6702652U (pt) Mesa regulavel para retroprojetores
ECSP961938A (es) Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n, n-caso x - 10386
BR6702169U (pt) Suportes para equilibrio e divercao pessoal

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567450

Country of ref document: ES